PARP inhibitors

Current Breast Cancer Reports

Volumn 3, Issue 1, 2011, Pages 44-54

  Liang, Hongyan ^a   Tan, Antoinette R ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

BRCA associated breast cancer; PARP inhibitor; Poly (ADP ribose) polymerase; Triple negative breast cancer

Indexed keywords

4 IODO 3 NITROBENZAMIDE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; INIPARIB; IRINOTECAN; MK 4827; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PF 01367338; SAR 240550; TEMOZOLOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; VELIPARIB;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG USE; FATIGUE; HUMAN; LYMPH NODE METASTASIS; MELANOMA; METASTASIS; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; SOLID TUMOR; SOMNOLENCE; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING;

EID: 79951809607     PISSN: 19434588     EISSN: 19434596     Source Type: Journal    
DOI: 10.1007/s12609-010-0036-y     Document Type: Article

References (60)

1. A Jemal R Siegel J Xu E Ward 2010 Cancer statistics, 2010 CA Cancer J Clin 60 277 300 10.3322/caac.20073 20610543
2. CT Brekelmans C Seynaeve M Menke-Pluymers, et al. 2006 Survival and prognostic factors in BRCA1-associated breast cancer Ann Oncol 17 391 400 1:STN:280:DC%2BD287ht1OksQ%3D%3D 10.1093/annonc/mdj095 16322115 (Pubitemid 43329574)
3. G Rennert S Bisland-Naggan O Barnett-Griness, et al. 2007 Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations N Engl J Med 357 115 123 1:CAS:528:DC%2BD2sXns12qsrk%3D 10.1056/NEJMoa070608 17625123 (Pubitemid 47057729)
4. R Dent M Trudeau KI Pritchard, et al. 2007 Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429 4434 10.1158/1078-0432.CCR-06-3045 17671126 (Pubitemid 47219710)
5. AR Tan SM Swain 2008 Therapeutic strategies for triple-negative breast cancer Cancer J 14 343 351 1:CAS:528:DC%2BD1MXhtVWrtLY%3D 10.1097/PPO. 0b013e31818d839b 19060597
6. LA Carey CM Perou CA Livasy, et al. 2006 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 2492 2502 1:CAS:528:DC%2BD28XlsV2rtLw%3D 10.1001/jama.295.21.2492 16757721 (Pubitemid 43854964)
7. JC Ame C Spenlehauer G de Murcia 2004 The PARP superfamily Bioessays 26 882 893 1:CAS:528:DC%2BD2cXnt1CqtLk%3D 10.1002/bies.20085 15273990 (Pubitemid 39128102)
8. V Schreiber F Dantzer JC Ame G de Murcia 2006 Poly(ADP-ribose): novel functions for an old molecule Nat Rev Mol Cell Biol 7 517 528 1:CAS:528:DC%2BD28Xms1Ohsb4%3D 10.1038/nrm1963 16829982 (Pubitemid 44036457)
9. H Otto PA Reche F Bazan, et al. 2005 In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs) BMC Genomics 6 139 10.1186/1471-2164-6-139 16202152 (Pubitemid 41554972)
10. A Tutt D Bertwistle J Valentine, et al. 2001 Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences EMBO J 20 4704 4716 1:CAS:528:DC%2BD3MXnt1Cmt7k%3D 10.1093/emboj/20.17.4704 11532935 (Pubitemid 32848624)
11. CJ Lord A Ashworth 2007 RAD51, BRCA2 and DNA repair: a partial resolution Nat Struct Mol Biol 14 461 462 1:CAS:528:DC%2BD2sXmtVyjt7g%3D 10.1038/nsmb0607-461 17549079 (Pubitemid 46871797)
12. JM de Murcia C Niedergang C Trucco, et al. 1997 Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells Proc Natl Acad Sci U S A 94 7303 7307 10.1073/pnas.94.14.7303 9207086 (Pubitemid 27345310)
13. A Ashworth 2008 A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair J Clin Oncol 26 3785 3790 1:CAS:528: DC%2BD1cXhtVGjs7rL 10.1200/JCO.2008.16.0812 18591545
14. HE Bryant N Schultz HD Thomas, et al. 2005 Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 913 917 1:CAS:528:DC%2BD2MXjtFOmsrY%3D 10.1038/nature03443 15829966 (Pubitemid 40559005)
15. H Farmer N McCabe CJ Lord, et al. 2005 Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 917 921 1:CAS:528:DC%2BD2MXjtFOmsrc%3D 10.1038/nature03445 15829967 (Pubitemid 40559006)
16. M Shrivastav LP De Haro JA Nickoloff 2008 Regulation of DNA double-strand break repair pathway choice Cell Res 18 134 147 1:CAS:528: DC%2BD1cXisVSjug%3D%3D 10.1038/cr.2007.111 18157161
17. PP Osin SR Lakhani 1999 The pathology of familial breast cancer: Immunohistochemistry and molecular analysis Breast Cancer Res 1 36 40 1:CAS:528:DC%2BD3cXlsFKgsbw%3D 10.1186/bcr11 11250681 (Pubitemid 32223534)
18. SR Lakhani MJ Van De Vijver J Jacquemier, et al. 2002 The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2 J Clin Oncol 20 2310 2318 1:CAS:528:DC%2BD38XktVKrs7o%3D 10.1200/JCO.2002.09.023 11981002 (Pubitemid 34441658)
19. A Catteau WH Harris CF Xu, et al. 1999 Methylation of the BRCA1 promoter region in sporadic breast cancer and ovarian cancer: correlation with disease characteristics Oncogene 18 1957 1965 1:CAS:528:DyaK1MXisVWmtb4%3D 10.1038/sj.onc.1202509 10208417 (Pubitemid 29150082)
20. G Baldassarre S Battista B Belletti, et al. 2003 Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma Mol Cell Biol 23 2225 2238 10.1128/MCB.23.7.2225-2238.2003 12640109 (Pubitemid 36351007)
21. L Hughes-Davies D Huntsman M Ruas, et al. 2003 EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer Cell 115 523 535 1:CAS:528:DC%2BD3sXps1Oht7c%3D 10.1016/S0092-8674(03)00930-9 14651845 (Pubitemid 37506042)
22. CK Donawho Y Luo TD Penning, et al. 2007 ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models Clin Cancer Res 13 2728 2737 1:CAS:528: DC%2BD2sXkslOhurg%3D 10.1158/1078-0432.CCR-06-3039 17473206 (Pubitemid 46795129)
23. Ossovskaya V, Li L, Broude EV, et al.: BSI-201 enhances the activity of multiple classes of cytotoxic agents and irradiation in triple negative breast cancer [abstract 5552]. Proc Am Assoc Cancer Res 2009.
24. LM Smith E Willmore CA Austin NJ Curtin 2005 The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks Clin Cancer Res 11 8449 8457 1:CAS:528:DC%2BD2MXht1KjsrbL 10.1158/1078-0432.CCR-05-1224 16322308 (Pubitemid 41746960)
25. SK Sandhu TA Yap JS de Bono 2010 Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective Eur J Cancer 46 9 20 1:CAS:528:DC%2BD1MXhsFGrsbjN 10.1016/j.ejca.2009.10.021 19926276
26. Underhill C, Toulmonde M, Bonnefoi H: A review of PARP inhibitors: from bench to bedside. Ann Oncol 2010, advanced access published July 19, 2010.
27. DV Ferraris 2010 Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic J Med Chem 53 4561 4584 1:CAS:528: DC%2BC3cXkt1WksLs%3D 10.1021/jm100012m 20364863
28. V Cepeda MA Fuertes J Castilla, et al. 2006 Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy Recent Pat Anticancer Drug Discov 1 39 53 1:CAS:528:DC%2BD28XhsFWrtr0%3D 10.2174/157489206775246430 18221025
29. PC Fong DS Boss TA Yap, et al. 2009 Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 123 134 1:CAS:528:DC%2BD1MXosVKrtrw%3D 10.1056/NEJMoa0900212 19553641
30. •• Tutt A, Robson M, Garber JE, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244. This is a proof-of-concept phase II trial of olaparib monotherapy in BRCA-associated advanced breast cancer. The study reported an ORR of 41% at the MTD of 400 mg orally twice daily and 22% at 100 mg orally twice daily.
31. MW Audeh J Carmichael RT Penson, et al. 2010 Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 245 251 1:CAS:528:DC%2BC3cXpt1Kktb4%3D 10.1016/S0140-6736(10)60893-8 20609468
32. Sandhu SK, Wenham RM, Wilding G, et al.: First-in-human trial of a poly (ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient and sporadic ovarian cancers [abstract 3001]. J Clin Oncol 2010, 28(Suppl 15).
33. Plummer R, Lorigan P, Evans J, et al.: First and final report of a phase II study of the PARP inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma [abstract 8013]. J Clin Oncol 2006, 24(Suppl 18).
34. Kopetz S, Mita MM, Mok I, et al.: First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors [abstract 3577]. J Clin Oncol 2008, 26(Suppl 15).
35. Mahany JJ, Lewis N, Heath EI, et al.: A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors [abstract 3579]. J Clin Oncol 2008, 26(Suppl 15).
36. •• O'Shaughnessy J, Osborne C, Pippen J, et al.: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin in patients with metastatic triple negative breast cancer: results of a randomized phase 2 trial [abstract 3]. J Clin Oncol 2009, 27(Suppl 18). This is a pivotal study that first reported the efficacy of iniparib in combination with chemotherapy in metastatic TNBC. In this multicenter, randomized phase II trial of gemcitabine and carboplatin given with or without iniparib to patients with metastatic TNBC, the addition of iniparib to chemotherapy resulted in an improved CBR and ORR compared to chemotherapy alone.
37. •• O'Shaughnessy J, Osborne C, Pippen J, et al.: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011, Jan 5 [Epub ahead of print]. This is the final efficacy and safety analysis of the multicenter, randomized phase II trial of gemcitabine and carboplatin given with or without iniparib to patients with metastatic TNBC. The report confirmed the earlier observation of improvement in CBR and ORR with iniparib added to the gemctiabine and carboplatin regimen. It also showed an improvement in OS, although the study was not powered for OS analysis.
38. BiPar Sciences Inc: Bipar Sciences announces update on the clinical development progress of BSI-201 for metastatic triple-negative breast cancer. Press Release December 11, 2009.
39. Dent R, Lindemann J, Clemons M, et al.: Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial [abstract 1018]. J Clin Oncol 2010, 28(Suppl 15).
40. Gelmon KA, Hirte HW, Robidoux A, et al.: Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian and triple-negative breast cancer [abstract 3002]. J Clin Oncol 2010, 28(Suppl 15).
41. Isakoff SJ, Overmoyer B, Tung NM, et al.: A phase II trial of the PARP inhibitor veliparib (ABT-888) and temozolomide for metastatic breast cancer [abstract 1019]. J Clin Oncol 2010, 28(Suppl 15).
42. O'Shaughnessy J, Osborne C, Pippen J, et al.: Final results of a randomized phase II study demonstrating efficacy and safety of BSI-201, a PARP inhibitor, in combination with gemcitabine/carboplatin in metastatic triple-negative breast cancer [abstract 3122]. Cancer Res 2009, 69(Suppl 3).
43. N McCabe NC Turner CJ Lord, et al. 2006 Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition Cancer Res 66 8109 8115 1:CAS:528:DC%2BD28XotFWqtLg%3D 10.1158/0008-5472.CAN-06-0140 16912188 (Pubitemid 44299177)
44. CM Annunziata J O'Shaughnessy 2010 Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer Clin Cancer Res 16 4517 4526 1:CAS:528:DC%2BC3cXhtFGqs7bO 10.1158/1078-0432.CCR-10-0526 20823142
45. CK Anders EP Winer JM Ford, et al. 2010 Poly(ADP-Ribose) polymerase inhibition: "Targeted" therapy for triple-negative breast cancer Clin Cancer Res 16 4702 4710 1:CAS:528:DC%2BC3cXht1aktbjM 10.1158/1078-0432.CCR-10- 0939 20858840
46. Rodriguez A, Rimawi M, Wu M, et al.: A BRCA-like, 25-gene assay predicts for anthracycline-chemosensitivity in sporadic triple-negative breast cancer [abstract 110]. Cancer Res 2009, 69(Suppl 24).
47. CA Banuelos JP Banath JY Kim C Aquino-Parsons PL Olive 2009 GammaH2AX expression in tumors exposed to cisplatin and fractionated irradiation Clin Cancer Res 15 3344 3353 1:CAS:528:DC%2BD1MXmtVKmurY%3D 10.1158/1078-0432.CCR-08- 3114 19401347
48. CE Redon AJ Nakamura YW Zhang, et al. 2010 Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers Clin Cancer Res 16 4532 4542 1:CAS:528:DC%2BC3cXhtFGqs7bI 10.1158/1078-0432.CCR-10-0523 20823146
49. H Liang AR Tan 2010 Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer IDrugs 13 646 656 1:CAS:528:DC%2BC3cXhtlGjurbE 20799148
50. CJ Lord A Ashworth 2008 Targeted therapy for cancer using PARP inhibitors Curr Opin Pharmacol 8 363 369 1:CAS:528:DC%2BD1cXhtFCktL7I 10.1016/j.coph.2008. 06.016 18644251
51. T Hay H Jenkins OJ Sansom, et al. 2005 Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy Cancer Res 65 10145 10148 1:CAS:528:DC%2BD2MXht1WgurnO 10.1158/0008-5472.CAN-05-1186 16287996 (Pubitemid 41743700)
52. P Pacher C Szabo 2007 Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors Cardiovasc Drug Rev 25 235 260 1:CAS:528:DC%2BD2sXht1yksbfN 10.1111/j.1527-3466.2007. 00018.x 17919258 (Pubitemid 47547464)
53. S Goldberg L Visochek E Giladi I Gozes M Cohen-Armon 2009 PolyADP-ribosylation is required for long-term memory formation in mammals J Neurochem 111 72 79 1:CAS:528:DC%2BD1MXht1ertLnN 10.1111/j.1471-4159.2009.06296. x 19645746
54. WM Tong YG Yang WH Cao, et al. 2007 Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice Oncogene 26 3857 3867 1:CAS:528:DC%2BD2sXlvFaksrg%3D 10.1038/sj.onc.1210156 17160013 (Pubitemid 46878132)
55. W Sakai EM Swisher BY Karlan, et al. 2008 Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers Nature 451 1116 1120 1:CAS:528:DC%2BD1cXisFWjt74%3D 10.1038/nature06633 18264087 (Pubitemid 351317449)
56. EM Swisher W Sakai BY Karlan, et al. 2008 Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platimum resistance Cancer Res 68 2581 2586 1:CAS:528:DC%2BD1cXks1Git7c%3D 10.1158/0008-5472.CAN-08-0088 18413725 (Pubitemid 351556255)
57. SL Edwards R Brough CJ Lord, et al. 2008 Resistance to therapy caused by intragenic deletion in BRCA2 Nature 451 1111 1115 1:CAS:528:DC%2BD1cXisFWjtrw%3D 10.1038/nature06548 18264088 (Pubitemid 351317441)
58. S Rottenberg JE Jaspers A Kersbergen, et al. 2008 High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Proc Natl Acad Sci U S A 105 17079 17084 1:CAS:528:DC%2BD1cXhtlKlsr7F 10.1073/pnas.0806092105 18971340
59. AstraZeneca: Second quarter and half year results 2010. Press Release July 29, 2010.
60. Abbott Laboratories: Second quarter and half year results 2010. Press Release July 21, 2010.